DAX ®12.798,19+0,34%TecDAX ®2.808,94-0,70%Dow Jones26.833,95+0,17%NASDAQ 1007.889,47+0,19%

PRESS RELEASE: MorphoSys to Present at Upcoming Investor Conferences

| Quelle: Dow Jones Newsw... | Lesedauer etwa 5 min. | Text vorlesen Stop Pause Fortsetzen

DGAP-News: MorphoSys AG / Key word(s): Conference
MorphoSys to Present at Upcoming Investor Conferences (news with additional

2019-05-23 / 22:01
The issuer is solely responsible for the content of this announcement.

Planegg/Munich, Germany, May 23, 2019

*MorphoSys to Present at Upcoming Investor Conferences*

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR)
will present at the following conferences:

*Jefferies Healthcare Conference*
Date: June 5, 2019, 8:00 am EDT ( 2:00 pm CEST, 1:00 pm BST)
Venue: New York, NY, U.S.
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG
Dr. Julia Neugebauer, Director Corporate Communications & IR

*dbAccess Berlin*
Date: June 6, 2019
Venue: Berlin, Germany
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
Dr. Verena Kupas, Manager Corporate Communications & IR

*Goldman Sachs 40th Annual Global Healthcare Conference*
Date: June 12, 2019
Venue: Los Angeles, CA, U.S.
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
Dr. Sarah Fakih, Head of Corporate Communications & IR

*J.P. Morgan European Healthcare Conference*
Date: June 20, 2019
Venue: London, UK
Presenter: Dr. Sarah Fakih, Head of Corporate Communications & IR
Dr. Julia Neugebauer, Director Corporate Communications & IR

*Meet the Team - Analyst and Investor Event*
Date: June 25, 2019, 10:00 am EDT ( 4:00 pm CEST, 3:00 pm BST)
Venue: New York, NY, U.S.
Participants: Management Team of MorphoSys AG and MorphoSys US Inc.

PDF versions of the presentations will be provided at www.morphosys.com [1].
Links to available webcasts will be filed under
www.morphosys.com/conference-calls [2].

About MorphoSys:
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company
dedicated to the discovery, development and commercialization of
exceptional, innovative therapies for patients suffering from serious
diseases. The focus is on cancer. Based on its leading expertise in
antibody, protein and peptide technologies, MorphoSys, together with its
partners, has developed and contributed to the development of more than 100
product candidates, of which 29 are currently in clinical development. In
2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis,
became the first drug based on MorphoSys's antibody technology to receive
regulatory approval. The Company's most advanced proprietary product
candidate, tafasitamab (MOR208), has been granted U.S. FDA breakthrough
therapy designation for the treatment of patients with relapsed/refractory
diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany,
the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US
Inc., has approximately 330 employees. More information at
https://www.morphosys.com [3].

arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio
Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys
Group. Tremfya(R) is a trademark of Janssen Biotech, Inc.

_MorphoSys forward looking statements_
This communication contains certain forward-looking statements concerning
the MorphoSys group of companies. The forward-looking statements contained
herein represent the judgment of MorphoSys as of the date of this release
and involve known and unknown risks and uncertainties, which might cause the
actual results, financial condition and liquidity, performance or
achievements of MorphoSys, or industry results, to be materially different
from any historic or future results, financial conditions and liquidity,
performance or achievements expressed or implied by such forward-looking
statements. In addition, even if MorphoSys's results, performance, financial
condition and liquidity, and the development of the industry in which it
operates are consistent with such forward-looking statements, they may not
be predictive of results or developments in future periods. Among the
factors that may result in differences are that MorphoSys's expectations may
be incorrect, the inherent uncertainties associated with competitive
developments, clinical trial and product development activities and
regulatory approval requirements (including that MorphoSys may fail to
obtain regulatory approval for tafasitamab (MOR208) and that data from
MorphoSys's ongoing clinical research programs may not support registration
or further development of its product candidates due to safety, efficacy or
other reasons), MorphoSys's reliance on collaborations with third parties,
estimating the commercial potential of its development programs and other
risks indicated in the risk factors included in MorphoSys's Annual Report on
Form 20-F and other filings with the U.S. Securities and Exchange
Commission. Given these uncertainties, the reader is advised not to place
any undue reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document.
MorphoSys expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based or that may affect the
likelihood that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or

*For more information, please contact:*

*MorphoSys AG*
Dr. Sarah Fakih
Head of Corporate Communications & IR

Alexandra Goller
Director Corporate Communications & IR

Dr. Julia Neugebauer
Director Corporate Communications & IR

Dr. Verena Kupas
Manager Corporate Communications & IR

*Tel: +49 (0) 89 / 899 27-404*

Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=REDNNAPPPH [4]
Document title: Conference Announcement

2019-05-23 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: investors@morphosys.com
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 815395

End of News DGAP News Service

815395 2019-05-23

1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=af6b62de1fd30b6c8f4ab4736ef0907c&application_id=815395&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=93d251a80a82730f0976114641593866&application_id=815395&site_id=vwd&application_name=news
3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=3e1886fbba4d35045db9993a27da4719&application_id=815395&site_id=vwd&application_name=news
4: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=53b72e264612e9efef909c0d923f6038&application_id=815395&site_id=vwd&application_name=news

(END) Dow Jones Newswires

May 23, 2019 16:01 ET ( 20:01 GMT)

Passende Hebelprodukte von

WKN Bezeichnung Hebel
Long  DS53S8 MORPHOSY WaveUnlimited S 115.2299 (DBK) 7,197

Das könnte Sie auch interessieren



Aktuelle Videos

zur Mediathek

Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Glauben Sie, dass die EZB in der heutigen Sitzung ein Stückchen an der lockeren Geldpolitik ändern wird?
Jetzt abstimmen!
Alle Umfragen ansehen